Two big names in research and medicine are joining forces to find a cure for HIV Aids.
UNC Chapel Hill and Glaxo-Smith Kline announced a public-private partnership to build an HIV Cure center on campus. GSK will invest $4 million a year for 5 years to pay for the initial research plan.
A small research team from GSK will move to Chapel Hill to be located with the UNC researchers.
“We look forward to seeing progress to the millions work like this,” commented Sir Andrew Witty, GSK CEO.
The focus will be on the latest scientific approaches to curing HIV, including an approach called “Shock and Kill” which is a way of trying to reveal the hidden virus that persists in people despite drug therapy.